StockData

Longeveron vs MediciNova

LGVN and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and MNOV compare

Longeveron and MediciNova are about the same size, with market caps of $67.3M and $66.0M.

MediciNova keeps more of each dollar of sales as profit, with a net margin of −1168% compared with −1978% at Longeveron.

MediciNova scores higher on the StockData Score (7 against 5 for Longeveron), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNMNOV
Size and price
Market cap$67.3M$66.0M
Share price$2.11$1.34
Change, 1 year−69.0%−13.5%
Change, 5 years−99.9%−58.4%
Beta (5Y)1.44−0.00
Employees376
StockData Score
Total score57 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S56.7× (better)71.7×
P/B6.5×1.8× (better)
FCF yield−30.5%−13.8% (better)
Growth
Revenue growth (TTM)−42.7%–
Revenue growth, 5Y average−26.6%–
Profitability
Gross margin69.8%–
Operating margin−1993%−1287% (better)
Net margin−1978%−1168% (better)
FCF margin−1730%−991% (better)
Return on equity−204%−25.6% (better)
Return on invested capital−1412%−76.6% (better)
Financial health
Debt / equity0.000.00
Current ratio2.638.75 (better)
Altman Z-score−9.42−3.11 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.5%10.5%
Held by insiders43.8%12.8%
Insider net buying, 12 months–−$1.7M
Short interest, % of float0.88%0.66%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.